November 6, 2017 06:30 PM EST
R&D

Watch out Sanofi: Takeda's new da­ta on dengue vac­cine is good news for PhI­II tri­al

Brittany Meiling

Prospects for Take­da’s dengue vac­cine just turned brighter fol­low­ing fresh da­ta from the com­pa­ny’s Phase II tri­al. For Take­da, the da­ta is like­ly wel­come con­sid­er­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times